VIRINCHIInformation Technology

Virinchi Limited

Software Products · ISIN INE539B01017 · BSE 532372 · NSE EQ · FV ₹10
Last price
₹14
-0.22%today
What this company does

Virinchi Limited operates in Software Products, part of the Information Technology sector. It booked ₹70 cr of revenue in its latest quarter (Q1 FY27) and kept 0.7% of sales as profit.

Statutory Reports Financial Statements Our key strengths The IT services division brings together deep industry The company’s captive internet data center provides experience and excellence in service delivery. Its a reliable base for future expansion into third-party core offerings include ERP, mobile platforms, cloud data center services.
In the report:
36out of 100
Equitytale Health Score
Strained

Healthier than 36% of companies in Information Technology, on all six measures of filed financials. Each measure is ranked against the 15–123 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
35

At close. Not part of the score.

Profitability & returns14

How much profit it earns on the money it employs

Balance sheet23

How much it owes, and whether earnings cover the interest

Cash quality89

Whether reported profit actually arrives as cash

Growth & consistency31

Whether sales and profit have grown, and how steadily

Valuation43

What today's price implies, against our models or its peers

Governance & risk38

How much of the promoters' stake is pledged, and how much they hold

Is this company doing well?
not investment advice
Strengths
Makes a profit
Profit up 12% vs last year
Turns profit into real cash
Watch-outs
! Thin 0.7% net margin
! Sales down 12% vs last year
! 17.2% of promoter stake pledged
! Low 0.4% return on equity

What if I invest in VIRINCHI?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 15% a year, it would become
₹26.30 lakh

The slider starts at 15%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹14 -0.22%
latest close · 2026-09-17
52-wk low ₹1442 sessions so far52-wk high ₹17
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio87.0High
LowAverageHigh
P/B ratio0.32Below book
Below bookModerateHigh
EV / EBITDA4.8Low
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity0.4%Weak
WeakFairStrong ▸15%
Return on capital0.8%Weak
WeakFairStrong
Net margin0.7%Thin
ThinDecentStrong
EBITDA margin21.3%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.29Comfortable
LowModerateHigh ▸1
Interest cover0.2×Risky
RiskyOkayStrong ▸5×
Current ratio1.69Healthy
Tight ◂1HealthyAmple
More figures
Market cap
₹157 cr
Book value
₹44
EPS
₹0.04
latest quarter
Net debt
₹133 cr
owes more than its cash
Enterprise value
₹290 cr
EBITDA
₹60 cr
annualised
EBIT
₹6 cr
annualised
Operating margin
2.1%
Return on assets
0.2%
Earnings yield
1.15%
P/S
0.56
Sales / share
₹24.9
Tax rate
Face value
₹10
Shares
11.3 cr
Working capital
₹91 cr
Current assets
₹224 cr
Current liabilities
₹132 cr
Delivery %
77.9%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the FY 2025 report & filings
not investment advice
Hard to value confidentlyLow confidence
The company's latest annual profit was negative, so we won't call it cheap off older profits.
Models span ₹12₹24, midpoint ₹18

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹70 cr
Other Income₹5.8 L
Total Income₹70 cr
Cost of Materials₹0 cr
Purchases of Stock-in-Trade₹4 cr
Inventory Change (±)₹-25.5 L
Employee Benefit Expense₹24 cr
Finance Costs₹8 cr
Depreciation & Amortisation₹13 cr
Other Expenses₹28 cr
Total Expenses₹77 cr
Profit before Tax₹-6 cr
Tax Expense₹-4 cr
Share of JV / Associates₹3 cr
Net Profit₹48.3 L
Net margin on total income0.7%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹4 cr4.8%
Employee benefit expense₹24 cr30.9%
Finance costs₹8 cr10.2%
Depreciation & amortisation₹13 cr17.5%
Other expenses₹28 cr35.9%
Profit for the period₹48.3 L0.6%
Total income ₹70 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue77 cr66 cr70 cr
Total income77 cr67 cr70 cr
Expenses73 cr80 cr77 cr
Profit before tax4 cr-18 cr-6 cr
Tax3 cr-3 cr-4 cr
Net profit (owners' share)2 cr-15 cr48.3 L
Net margin (owners' share, on revenue)2.2%-22.2%0.7%
EPS (₹)0.14-1.380.04
YoY (latest quarter): total income -12.0% · net profit +11.6%
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹850 cr
Shareholder equity
₹493 cr
parent shareholders
Total debt
₹141 cr
Cash
₹9 cr
Cash flow · H1 FY26
Operating
₹7 cr
Investing
₹-4 cr
Financing
₹-5 cr
Peer comparison
Software Products · by market value
CompanyPriceMarket capP/E
Oracle Financial Services Software Limited₹11,620₹1.01 L cr17.9
Tanla Platforms Limited₹495₹6,567 cr11.5
C.E. Info Systems Limited₹890₹4,872 cr24.5
Capillary Technologies India Limited₹449₹3,568 cr
Ramco Systems Limited₹565₹2,125 cr882.6
Nucleus Software Exports Limited₹691₹1,820 cr19.1
Subex Limited₹20₹1,118 cr19.1
Quick Heal Technologies Limited₹152₹827 cr
Unicommerce Esolutions Limited₹84₹806 cr43.1
Same industry · latest reported numbers · not a recommendation.
Corporate actions
Dividend yield
trailing 12 months
Dividend / share (TTM)
Last dividend
₹0.5
ex 17 Sep 2012
ActionDetailEx-date
Bonus issue1:121 Mar 2022
Dividend₹0.5 / share17 Sep 2012
Who owns it · 2026-06-30
17.2% pledged
Promoter
39.5%
FII / Foreign
0.0%
DII / Domestic
Retail / others
60.5%
Promoter stake up 1.2% over the last 12 quarters.
Smart-money activity
Bulk / block deals
BoughtGREEN FIELD MEADOWS INFRA PRIVATE LIMITED · NSE5.88 L @ ₹28.5710 Jul 25
BoughtSAMIR NARENDRA GUPTA · NSE5.15 L @ ₹21.728 Apr 25
SoldNARENDRAKUMAR BHAGWANDAS GUPTA · NSE5.15 L @ ₹21.728 Apr 25
Stake changes
BoughtMr. Viswanath Kompella · promoter→ 11.31% · 20,00016 Mar 26
BoughtVivo Bio Tech Limited · promoter→ 4.69% · 13.16 L24 Feb 26
BoughtVivo Bio Tech Ltd · promoter→ 12.69%5 Feb 26
Promoter pledges
ReleasedIIFL Securites Ltd30.00 L · 2.92% held24 Apr 25
PledgedIIFL Securities Ltd30.00 L · 0.00% held22 Apr 25
PledgedBadjate Stocke Broking Pvt Ltd5.00 L · 10.49% held15 Apr 25
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Postal ballot · 10 Aug 2026
See the official result
1
Approval for Acquisition of the Primary and Secondary Healthcare Business Division under Bristlecone Hospitals Brand from Virinchi Health Care Private Limited, a Material Subsidiary of the Company, on a Slump Sale Basis
Promoters had a personal stake in this
Backed by 95% of shareholders other than promotersneeded 50%
52.42 L votes for, 2.69 L against

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 15 named members
owning 39.5% between them · as of 2026-06-30
VISWANATH KOMPELLA14.53%
GAJWEL DEVELOPERS PRIVATE LIMITED5.32%
VIVO BIO TECH LIMITED5.28%
KOMPELLA RAMAKRISHNA PARAMAHAMSA3.85%
LOPA MUDRA KOMPELLA3.57%
PKI SOLUTIONS PRIVATE LIMITED3.49%
PRAVEEN KUMAR KONDAI1.20%
KOMPELLA MODINI1.06%
Business done with them
FY2025 · 1 of the group
The company paid ₹3 cr to companies in the promoter group last year — about 1.1% of its ₹301 cr revenue.
VISWANATH KOMPELLA
Other payments to them · REMUNERATION FOR ADVISORY SERVICES
also owns 14.53% of the company
₹3 cr
company paid

The company also transacted with 14 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.